Stock JENBURPH6 JENBURKT PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Jenburkt Pharmaceuticals Limited

Equities

JENBURPH6

INE354A01013

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:01:01 2024-07-05 am EDT 		5-day change 1st Jan Change
877.6 INR -0.10% Intraday chart for Jenburkt Pharmaceuticals Limited +0.59% +29.02%
May. 28 Jenburkt Pharmaceuticals Limited Announces Board Retirements CI
May. 28 Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI

Business Summary

Jenburkt Pharmaceuticals Limited is an India-based company that is engaged in the business of manufacturing, producing, developing and marketing a range of branded pharmaceuticals and health care products. The Company offers pharmaceutical products for various therapeutic areas, analgesic and antipyretics anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants/antacids, aphrodisiac, consumer division, cough and cold, muscle relaxants neuropathic pain, nutraceuticals and pain management. The Company's product brands include Allerzine tablets, Cartisafe forte MSM tablets, Eberjen Cream and SOL, ECOPROT powder, Frendacid suspension, Fundu tablets, Glajen-E capsules, GLUCOTROL tablets, Jenflam tablets, Lutriben cream, Ornel tablets, Pantazole tablets and others. The Company's manufacturing plant is located in Sihor-Gujarat. The Company's products are exported to approximately 13 countries globally.

Number of employees: 752

Sales per Business

INR in Million2023Weight2024Weight Delta
Pharmaceutical Formulations
99.8 %
1,361 99.6 % 1,416 99.8 % +4.03%
Other
0.2 %
6 0.4 % 3 0.2 % -45.28%

Sales per region

INR in Million2023Weight2024Weight Delta
India
85.9 %
1,109 81.4 % 1,216 85.9 % +9.67%
International
14.1 %
253 18.6 % 200 14.1 % -20.73%

Managers

Managers TitleAgeSince
Ashish Uttam Bhuta CEO
 Chief Executive Officer - 10-01-07
Dilip Harkisandas Bhuta DFI
 Director of Finance/CFO 72 13-09-06
Ashish Rasiklal Shah CMP
 Compliance Officer - -
Vijayan J. Pillai IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Ashish Uttam Bhuta CEO
 Chief Executive Officer - 10-01-07
Dilip Harkisandas Bhuta DFI
 Director of Finance/CFO 72 13-09-06
Hina Ravindra Mehta BRD
 Director/Board Member 61 20-03-27
Sumit Ajaybhai Thakkar BRD
 Director/Board Member 41 23-07-25

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 4,413,300 1,718,570 ( 38.94 %) 0 38.94 %

Company contact information

Jenburkt Pharmaceuticals Ltd.

Nirmala Apartments 93, Jayprakash Road

400058, Mumbai

+91 22 6760 3603

http://www.jenburkt.com
address Jenburkt Pharmaceuticals Limited(JENBURPH6)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Sector Other Pharmaceuticals

1st Jan change Capi.
JENBURKT PHARMACEUTICALS LIMITED Stock Jenburkt Pharmaceuticals Limited
+29.02% 46.39M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 823B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 627B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.99% 320B
ABBVIE INC. Stock AbbVie Inc.
+7.92% 295B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 239B
NOVARTIS AG Stock Novartis AG
+13.83% 220B
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
AMGEN INC. Stock Amgen Inc.
+7.94% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JENBURPH6 Stock
  4. Company Jenburkt Pharmaceuticals Limited